Elsevier Foundation Seeks Grant Proposals for I...
NEW YORK, June 24 /PRNewswire/ --
- Awards Target Researchers in Developing Countries and Academic
Workplace
The Elsevier Foundation is seeking grant proposals for its Innovative
Libraries in Developing Countries and New Scholars programs. Grant proposals
for the two programs sponsored by Elsevier, a leading global publisher of
scientific, technical and medical information products and services, are due
by September 15, 2008. The grants will be awarded in December 2008 and
provide one, two and three year awards between US$5,000 to US$50,000 per
year.
The program for Innovative Libraries in Developing Countries
(http://www.elsevierfoundation.org/library.html) helps libraries enhance the
quality of life in developing countries by improving their ability put
scientific, technical and medical information to work for those who need it.
The New Scholars (http://www.elsevierfoundation.org/scholar.html) program
helps the academic and research communities create model programs to help
scholars in the early stages of their careers balance childcare and family
responsibilities with the demanding academic careers in science, health and
technology.
Active since 2002, the Elsevier Foundation provides grants to
institutions around the world, with a focus on support for the world's
libraries and for scholars in the early stages of their careers. Since its
inception, the Foundation has awarded more than 50 grants worth over a
million dollars to non-profit organizations working in these fields. Through
gift-matching, the Foundation also supports the efforts of Elsevier employees
to play a positive role in their local and global communities.
For more information on the program requirements and details of how to
submit a proposal please visit http://www.elsevierfoundation.org/index.html .
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical
information products and services. Working in partnership with the global
science and health communities, Elsevier's 7,000 employees in over 70 offices
worldwide publish more than 2,000 journals and 1,900 new books per year, in
addition to offering a suite of innovative electronic products, such as
ScienceDirect (http://www.sciencedirect.com/), MD Consult
(http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in
Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of
Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading
publisher and information provider. Operating in the science and medical,
legal, education and business-to-business sectors, Reed Elsevier provides
high-quality and flexible information solutions to users, with increasing
emphasis on the Internet as a means of delivery. Reed Elsevier's ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).
Media Contact:
Ylann Schemm
Elsevier Corporate Relations
+31-20-485-2025
newsroom@elsevier.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.